Research and Clinical Trials

Title  
FORMA Therapeutics 1101-HEM-101:A Phase 1 Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 in Patients with Relapsed or Refractory Hematologic Malignancies
Brief Description  
To determine the maximum tolerated dose (MTD), the dose limiting toxicities(DLT) and the dose of FT-1101 recommended for future phase 2 studies (RP2D) for patients with relapsed refractory acute leukemia or high-risk MDS.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Other Hematopoietic
Status  
OPEN
Start Date  
10/05/2015
IRB Number  
00013227
Principal Investigator  
Grunwald, Michael Richard
Contact Name  
Angela P Anderson

For More Information, Contact  Angela  P, Anderson
Phone:  980-442-2365 Fax:    
Email:  Angela.P.Anderson@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, NC 28204
Close